Snegha Ananth (@SneghaAnanth) header
Snegha Ananth (@SneghaAnanth) profile picture

Asst Professor @unmchemeonc. Alumni @uthsaim @stanford Lymphoma/MRD/CAR-T/AlloSCT #Womeninmedicine 👨‍👩‍👦🇮🇳🇺🇸

USA
Joined December 2017
Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)Photo by Snegha Ananth (@SneghaAnanth)
Thanks @DrJulieVose! UNMC is one of the few institutes that already incorporates MRD testing in our SOP for lymphoma patients. Looking forward to build upon more knowledge and clarity regarding MRD testing in lymphoma.
Dr. Snegha Ananth presenting important data on ctDNA post CART and predictive values for relapse. #ASH2025 Great job! @NebraskaMed @UNMCHemeOnc
1
6
573
Thank you @lymphomaphilia for the shoutout. Excited to take this further with our IIT. #ASH25
Dr. Ananth rocks the stage with data from her time at Stanford questioning whether we “need” PET/CT post CAR-T in LBCL if uMRD6 at D=14! Great presentation, UNMC is lucky have her as faculty!
1
197
Presented real-world ClonoSEQ MRD kinetics after axi-cel and liso-cel at #ASH25, exploring MRD-guided surveillance . Happy to build on a work started as a @StanfordBMT_CT fellow and now continuing to expand as a faculty. Slides in thread..(#1/4)
1
1
2
117
D14 MRD stratified outcomes after axi-cel; detectable MRD had ~3.5 mo PFS. A potential window for consolidation trials. Need larger numbers for liso-cel.(#3/4)
1
59
Simulation suggests early MRD- pts rarely relapse, supporting MRD-guided surveillance with PET limited to early MRD+, MRD conversion, or symptoms. Extra-nodal/small lesions still warrant PET. Encouraging for prospective evaluation.(#4/4)
46
Snegha Ananth retweeted
HLH (“IEC-HS”) is hard to distinguish from CRS and other diagnoses after CAR T cells, Also, cytopenias (ICAHT) are common after CAR T and stem cell boost is the only known effective solution. Interestingly, boost was seen to fuel the fire of IEC-HS here: ashpublications.org/bloodadv…
3
18
3
33
5,655
Our report on 2 cases of recurrent IEC-HS after Cilta-cel: Inflammation begets inflammation. Identify early cytopenia etiology before stem cell boost & monitor for recurrence. Better bridging options may reduce severe toxicities. @SurbhiSidanaMD ashpublications.org/bloodadv…
2
7
846
Lucky to be a part of this team! 😇
⁦@UNMCHemeOnc⁩ @Buffett Cancer Center Lymphoma Team meeting prior to #ICML25 ! Working on the next great clinical trial!
4
252
Presented my ctDNA work in lymphoma this week at #ICML2025! Clonoseq assay shows prognostic value as early as day 14 and helps clarify PET scan ambiguity in the post–Axi-cel setting. More data pending! Poster number 427. Thanks to my mentor Dr. Matthew Frank from @StanfordBMT_CT
5
4
12
644
Presenting my Stanford work at #EHA2025 in the beautiful city of Milan. Thanks to @MelodySmithMD and @LoriMuffly mentorship - my first experience working with correlative research in this innovative trial combining allogeneic transplant and Allo-CAR T-cell therapy for B-ALL.
1
1
1
18
2,127
I used to give my patients a generic “lead a healthy lifestyle” during/after cancer treatment and sometimes felt like I wasn’t truly helping. Now I can confidently say: it matters. A healthy lifestyle is key to recovery, resilience, and reducing recurrence.
Just brand it “Exercizumab!” 😃 In all seriousness, I have been recommending exercise during & after treatment to all my patients who are able to. Great to have Level 1 evidence supporting this strategy. Now need systematic change to upscale & implement. #ASCO25
1
6
402
New malignancies and nonrelapse mortalities were rare, occurring in 4 and 2 patients each, and none was related to axi-cel. ow.ly/1MGx50VTZy3 #cartcell #cart #lymsm #lymphoma
2
11
46
4,567
Snegha Ananth retweeted
Listen to @crdangelo9 and @SneghaAnanth, both from @UNMC @NebraskaMed, and Dr. Kailash Mosalpuria at NHO to talk about #lymphoma at #NebraskaHeme25 on Apr 12! Session chair: Dr. Mehmet Sitki Copur (@MLHealthcare) Register NOW: education.binayfoundation.or… #MedTwitter #MedX #MedEd
1
3
253
Congratulations Dr. Bharadwaj and grateful to Dr. Weng for leading this fellowship. One of the best experiences I’ve had in my career :)
Nice to see this re: @StanfordBMT_CT BMT/CT fellowship program (Bharadwaj @LMikkMD @MelodySmithMD et al) Now >17 years of training physicians (many initially on visa) to become academic BMT/CT experts and further advance our field 👏 Including @hemedoc! link.springer.com/article/10…
2
2
1,640
My first month as an attending at @UNMCHemeOnc has been an incredible experience, thanks to an amazing and welcoming team! Grateful to work alongside @DrJulieVose and everyone here (including the photobombers 😉)—@LightTheNight by @LLSusa
1
1
1
14
1,394
Graduated from @StanfordBMT_CT – marking the end of my 15-year journey of medical education. Like a bamboo shoot that has spent years preparing, I'm now ready to grow and learn at my first ever job! 🌱
14
3
2
84
8,295
⁦@TomBmt133⁩ asked, now that MRD is accepted endpoint for accelerated approvals, how do harmonize MRD across clinical trials? Here is a start: International harmonization in performing and reporting MRD in MM trials | Leukemia nature.com/articles/s41375-0…
2
11
34
3,880